A paper published in the June issue of Obstetrics & Gynecology demonstrated that adding OVA1 to a physician's preoperative assessment of a woman's ovarian mass would identify more ovarian cancers than ...

A study published online ahead of print in the June 2011 edition of Obstetrics & Gynecology demonstrated that American College of Obstetrics and Gynecology (ACOG) guidelines for determining the ...

MADISON, N.J. and AUSTIN, Texas, May 12, 2011 /PRNewswire/ -- A study published online ahead of print in the June 2011 edition of Obstetrics & Gynecology demonstrated that American College of ...

MADISON, N.J. and FREMONT, Calif., March 9 OVA1(TM), the first blood test cleared by the U.S. Food and Drug Administration (FDA) for aiding in the pre-surgical evaluation of a woman's ovarian mass for ...

Replacing CA125 with the OVA1 multivariate index assay may better predict whether an ovarian mass is cancerous in premenopausal women and those with early-stage disease, according to data from a study ...

"We are pleased to expand the in-network coverage for OVA1 with the signing of these agreements," said Fred Ferrara, Chief Operating Officer of Vermillion, Inc. "These agreements increase coverage in ...

Vermillion, Inc.'s OVA1® has received a new statement on clinical validation and medical use issued by the Society of Gynecologic Oncology (SGO). Citing peer-reviewed publications from two pivotal ...

A new study of OVA1 clinical performance in the presurgical detection of ovarian cancer, entitled "Clinical Performance of a Multivariate Index Assay For Detecting Early-Stage Ovarian Cancer," has ...

AUSTIN, Texas, June 10, 2020 (GLOBE NEWSWIRE) -- Vermillion, Inc. (VRML), a bioanalytical-based women’s health company focused on gynecologic disease, is excited to announce that its wholly-owned ...

AIM is a wholly owned subsidiary of Anthem, Inc., serving more than 50 million members across 50 states, D.C., and US territories. AUSTIN, Texas, July 08, 2021 (GLOBE NEWSWIRE) -- Aspira Women’s ...

- Milestone data announced during Ovarian Cancer Awareness Month, which demonstrates OVA1’s superior sensitivity of ovarian cancer risk detection in both Caucasian and African American women versus ...